CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks——Favorable ...
CervoMed: Neflamapimod Phase 2b Trial In Dementia With Lewy Bodies Patients Fails To Meet Targets
CervoMed Inc. (CRVO) announced Tuesday that its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia ...
CervoMed’s stock craters 77% after failed trial of treatment for rare brain disease
CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with ...
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
CervoMed reports RewinD-LB trial results for neflamapimod in dementia with Lewy bodies, highlighting missed endpoints and ...
CervoMed price target lowered to $4 from $45 at Roth MKM
Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company ...
CervoMed's dementia drug fails mid-stage trial, shares slump
CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary ...
CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint
CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet ...
tyla9d
Unexpected symptom that could actually be an early warning sign of dementia
Along with memory problems, losing your sense of smell could be an early indicator of dementia. According to a report in ...
CervoMed Phase 2b Study of Neflamapimod Misses Main Endpoints
CervoMed on Tuesday said a mid-stage study of its lead program neflamapimod missed its key goals in the degenerative brain disease dementia with Lewy bodies, or DLB.
Medpage Today on MSN2d
Brain Aging Biomarkers; Midlife Anxiety and Dementia Risk; Who Chose Assisted Dying?
Researchers identified 13 proteins that predicted how quickly or slowly a person's brain aged. (Nature Aging) Midlife anxiety ...
Medical Xpress on MSN16d
New biomarkers could improve diagnosis and tracking of Parkinson's disease and Lewy body dementia
"Currently, the field has been using clinically defined diagnostic criteria of Parkinson's disease or dementia with Lewy ...
Hosted on MSN4d
Daily blood cancer tablet could slow or reverse dementia, study claims
cognition and memory in patients with Lewy body dementia – a form of dementia caused by protein deposits known as Lewy bodies which develop in the brain. Experts believe nilotinib – which works by ...